Fig 1: Expression of TRIM65 is negatively correlated with LATS1. (a) Other proteins were differentially expressed after sh-TRIM65 expression by LC-MS. (b) Correlation expression of TRIM65 with LATS1 and LATS2 based on StarBase database. (c) Knockdown of TRIM65 increased expression of LATS1 but not LATS2 in MDA-MB-231 and MDA-MB-453 cell lines. p < 0.05, p < 0.01, and p < 0.001 were considered statistically significant.
Fig 2: LATS2 suppressed cell migration and invasion. (A) Scratch wound healing assay was performed in U-372 MG cells transfected with LATS2 (left) or siLATS2 (right) for 24 h. Wound repair rate was inversely related to the expression levels of LATS2. Representative images (magnification, ×200) of wound closure at 0 and 24 h are shown. Black dotted lines indicate initial injury at 0 h and injury closure at 24 h. (B) Cell migration was quantified as a percentage of the healed area. (C) Transwell invasion assay was performed in U-372 MG cells transfected with LATS2 (left) or siLATS2 (right). Representative images (magnification, ×400) of invasive cells are shown. The number of invasive cells was counted and was inversely related to the expression levels of LATS2. All data are presented as the means ± standard deviation (n=3). **P<0.01; ***P<0.001 compared with control or siNC groups. Each assay was performed in triplicate. LATS2, large tumor suppressor kinase 2; NC, negative control; si/siRNA, small interfering RNA.
Fig 3: LATS1 and LATS2 expression and outcome in ovarian cancer (transcriptomic data). a, b Forest plot presenting hazard ratios (HR) computed from different transcriptomic data sets for LATS1 and LATS2 in ovarian cancer
Fig 4: LATS2 was downregulated in glioma. (A) Expression levels of LATS2 were significantly lower in astrocytomas, oligodendrogliomas and glioblastomas compared with in normal tissues, as detected by reverse transcription-quantitative polymerase chain reaction. (B) Representative immunohistochemistry images (magnification, ×200) of LATS2 in astrocytomas, oligodendrogliomas and primary glioblastomas. (C) Number of positive cells in immunohistochemistry was calculated. (D) mRNA expression levels of LATS2 in glioma cell lines (U-372 MG, LN-229, U-251 MG and A172) were lower than in the normal glial cell line (HEB); U-372 MG cells had the lowest expression of LATS2. Data are presented as the means ± standard deviation. **P<0.01; ***P<0.001 compared with the normal group or HEB cells. LATS2, large tumor suppressor kinase 2.
Fig 5: LATS1, LATS2, and MDR1 expression (a) in cisplatin-resistant A2780/CP (16-fold) and TYK-nu(R) (4-fold: Kohler et al. 2017) and paclitaxel-resistant IGROV1-PXL (9.3-fold; Kohler et al. 2017) cells and in the respective parental cell lines. Resistance determined for IC50 values from MTT assays (b)
Supplier Page from Abcam for Anti-LATS2 antibody